Conflict

of interest Michael J. Rybak has received grant support, has served as a consultant, or has participated as a speaker for Cubist, Durata, Forest, Theravance and Trius Pharmaceuticals. Hossein Salimnia has received grant support from BioFire Inc. Keith S. Kaye has received grant support, has served as a consultant, or has participated as a speaker for Cubist. Molly E. Steed, Ashley D. Hall, and Glenn W. Kaatz have no conflicts to declare. Compliance with ethics guidelines This article does not contain any studies with human or animal subjects performed by any of the authors. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Electronic supplementary material Below is the Eltanexor link to the

electronic Selleck Bafilomycin A1 supplementary material. Supplementary material 1 (PDF 205 kb) References 1. Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601–8.PubMedCrossRef 2. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(8):2538–44.PubMedCentralPubMedCrossRef 3. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63–8.PubMedCentralPubMedCrossRef 4. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy. 2004;24(1):41–57.PubMedCrossRef

5. Clinical and Selleckchem CDK inhibitor Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—ninth edition: approved standard M7-A9. Wayne: CLSI; 2011. 6. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45(6):1799–802.PubMedCentralPubMedCrossRef 7. Rose WE, Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas Axenfeld syndrome G. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother. 2007;59(6):1190–3.PubMedCrossRef 8. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.PubMedCrossRef 9. Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005–2010). Diagnostic microbiology and infectious disease. 2011;70(3):412–6 (Research Support, Non-U.S. Gov’t).PubMedCrossRef 10.